Issue

Vol 26 No Supplementary Issue

Copyright (c) 2014 Muchtaridi Muchtaridi1, Choi Sy Bing2, Aisyah S. Abdurrahim3, Habibah A. Wahab2

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Evidence of Combining Pharmacophore Modeling-Docking Simulation for Screening on Neuraminidase Inhibitors Activity of Natural Product Compounds

https://doi.org/10.14233/ajchem.2014.19013
Muchtaridi Muchtaridi1
1Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Indonesia 2Malaysian Institute of Pharmaceuticals and Nutraceuticals, Ministry of Science, Technology and Innovation, Penang, Malaysia 3School of Pharmaceutical Sciences, University Sains Malasysia, 11800, Penang, Malaysia *Corresponding author: E-mail: muchtaridi@unpad.ac.id
Choi Sy Bing2
1Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Indonesia 2Malaysian Institute of Pharmaceuticals and Nutraceuticals, Ministry of Science, Technology and Innovation, Penang, Malaysia 3School of Pharmaceutical Sciences, University Sains Malasysia, 11800, Penang, Malaysia *Corresponding author: E-mail: muchtaridi@unpad.ac.id
Aisyah S. Abdurrahim3
1Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Indonesia 2Malaysian Institute of Pharmaceuticals and Nutraceuticals, Ministry of Science, Technology and Innovation, Penang, Malaysia 3School of Pharmaceutical Sciences, University Sains Malasysia, 11800, Penang, Malaysia *Corresponding author: E-mail: muchtaridi@unpad.ac.id
Habibah A. Wahab2
1Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Indonesia 2Malaysian Institute of Pharmaceuticals and Nutraceuticals, Ministry of Science, Technology and Innovation, Penang, Malaysia 3School of Pharmaceutical Sciences, University Sains Malasysia, 11800, Penang, Malaysia *Corresponding author: E-mail: muchtaridi@unpad.ac.id

Corresponding Author(s) : Muchtaridi Muchtaridi1

Asian Journal of Chemistry, Vol 26 No Supplementary Issue

Abstract

In this study, chemical features of 3D-pharmacophore were built to screen of neuraminidase inhibitors from natural products. The pharmacophore hypothesis selected had five features [one hydrogen bond donor, one negative ionizable (N), one positive ionizable (P) and two hydrophobic moiety (Hy)], also included two excluded volume. The best pharmacophore was created by hypogen in DS 2.5 which has a lowest total cost value (92.055), the highest cost difference (107.807), the lowest RMSD (1.197) and the best correlation coefficient (0.944651). The screening of NADI database natural compounds shows that 167 compounds of 3000 NADI compounds were mapped by using four feature at this screening by optimizing the minimum predicted activity to 0.41. In a docking study, good bonding interaction has been shown by coumarilquinic acid derivatives of NADI compounds mapped against neuraminidase (1FD8B), but only MSC927 has a free energy docking score smaller than DANA-1F8B (-9.56 kcal/mol). We have proved both these methods pharmacophore and docking with the statistic and assay experiment methods. Receiver operating under curve in statistic methods have high value (0.907), whereas MUNANA assay experiment resulted that MSC927 has IC50 smaller than others as mention in silico resulted.

Keywords

Neuraminidase Pharmacophore Docking Virtual screening Nature based drug discovery.
Muchtaridi1, M., Sy Bing2, C., S. Abdurrahim3, A., & A. Wahab2, H. (2014). Evidence of Combining Pharmacophore Modeling-Docking Simulation for Screening on Neuraminidase Inhibitors Activity of Natural Product Compounds. Asian Journal of Chemistry, 26(27), 59–63. https://doi.org/10.14233/ajchem.2014.19013
Download Citation
Endnote/Zotero/Mendeley (RIS)
BibTeX
References
  1. G.M. Air and W.G. Laver, Proteins, 6, 341 (1989).
  2. M. von Itzstein, J.C. Dyason, S.W. Oliver, H.F. White, W.-Y. Wu, G.B. Kok and M.S. Pegg, J. Med. Chem., 39, 388 (1996).
  3. O. Dror, D. Schneidman-Duhovny, Y. Inbar, R. Nussinov and H.J. Wolfson, J. Chem. Inf. Model., 49, 2333 (2009).
  4. H.A. Wahab, R.M. Asarudin, S. Ahmad et al., Nature Based Drug Discovery (NADI) & Its Application to Novel Neuraminidase Inhibitors Identification by Virtual Screening, Pharmacophore Modelling and Mapping of Malaysian Medicinal Plants.
  5. B.R. Brooks, R.E. Bruccoleri, B.D. Olafson, D.J. States, S. Swaminathan and M. Karplus, J. Comput. Chem., 4, 187 (1983).
  6. H.Y. Wang, Z.X. Cao, L.L. Li, P.-D. Jiang, Y.-L. Zhao, S.-D. Luo, L. Yang, Y.-Q. Wei and S.-Y. Yang, Bioorg. Med. Chem. Lett., 18, 4972 (2008).
  7. X.Q. Deng, H.Y. Wang, Y.L. Zhao, M.-L. Xiang, P.-D. Jiang, Z.-X. Cao, Y.-Z. Zheng, S.-D. Luo, L.-T. Yu, Y.-Q. Wei and S.-Y. Yang, Chem. Biol. Drug Des., 71, 533 (2008).
  8. B.J. Smith, P.M. Colman, M. Von Itzstein, B. Danylec and J.N. Varghese, Protein Sci., 10, 689 (2001).
  9. G.M. Morris, R. Huey and A.J. Olson, Using AutoDock for Ligand-Receptor Docking, Current Protocols in Bioinformatics, Chapter 8, Unit 8.14 (2008).
  10. A. Hurt, Fluorometric Neuraminidase Inhibition Assay, WHO Collaborating Centre for Reference and Research on Influenza, pp. 1-10 (2007).
  11. V.R. Atigadda, W.J. Brouillette, F. Duarte, Y.S. Babu, S. Bantia, P. Chand, N. Chu, J.A. Montgomery, D.A. Walsh, E. Sudbeck, J. Finley, G.M. Air, M. Luo and G.W. Laver, Bioorg. Med. Chem., 7, 2487 (1999).
  12. P. Chand, S. Bantia, P.L. Kotian, Y. El-Kattan, T.-H. Lin and Y.S. Babu, Bioorg. Med. Chem., 13, 4071 (2005).
  13. P. Chand, P.L. Kotian, A. Dehghani, Y. El-Kattan, T.-H. Lin, T.L. Hutchison, Y.S. Babu, S. Bantia, A.J. Elliott and J.A. Montgomery, J. Med. Chem., 44, 4379 (2001).
  14. P. Chand, P.L. Kotian, P.E. Morris, S. Bantia, D.A. Walsh and Y.S. Babu, Bioorg. Med. Chem., 13, 2665 (2005).
  15. C.U. Kim, W. Lew, M.A. Williams, H. Wu, L. Zhang, X. Chen, P.A. Escarpe, D.B. Mendel, W.G. Laver and R.C. Stevens, J. Med. Chem., 41, 2451 (1998).
  16. W. Lew, P.A. Escarpe, D.B. Mendel, D.J. Sweeny and C.U. Kim, Bioorg. Med. Chem. Lett., 9, 2811 (1999).
  17. W. Lew, H. Wu, D.B. Mendel, P.A. Escarpe, X. Chen, W.G. Laver, B.J. Graves and C.U. Kim, Bioorg. Med. Chem. Lett., 8, 3321 (1998).
  18. N. Triballeau, F. Acher, I. Brabet, J.-P. Pin and H.-O. Bertrand, J. Med. Chem., 48, 2534 (2005).
  19. C.A. Lipinski, F. Lombardo, B.W. Dominy and P.J. Feeney, Adv. Drug Deliv. Rev., 46, 3 (2001).
  20. R.J. Russell, L.F. Haire, D.J. Stevens, P.J. Collins, Y.P. Lin, G.M. Blackburn, A.J. Hay, S.J. Gamblin and J.J. Skehel, Nature, 443, 45 (2006).
  21. M. Sefkow, A. Kelling and U. Schilde, Eur. J. Org. Chem., 2735 (2001).
  22. M.N. Clifford, S. Marks, S. Knight and N. Kuhnert, J. Agric. Food Chem., 54, 4095 (2006).
  23. H.-J. Luo, J.-Z. Wang, J.-F. Chen and K. Zou, Med. Chem. Res., 20, 554 (2011).
  24. I. Koji, Y. Makoto and N. Takehiko, Neuraminidase Inhibitory Component, N. A. F. R. Organization, Japan (2011).
Read More
Author biographies is not available.
Download
Statistic
Read Counter : 0